AAAAAA
Results: 1-25/31
Authors:
HANG MTN
RANSON M
SAUNDERS DN
LIANG XM
BUNN CL
BAKER MS
Citation: Mtn. Hang et al., PHARMACOKINETICS AND BIODISTRIBUTION OF RECOMBINANT HUMAN PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-2 (PAI-2) IN CONTROL AND TUMOR XENOGRAFT-BEARING MICE, FIBRINOLYSIS & PROTEOLYSIS, 12(3), 1998, pp. 145-154
Authors:
THATCHER N
RANSON M
ANDERSON H
BURT P
DAVIDSON N
NICOLSON M
FALK S
CARMICHAEL J
WASHINGTON T
JEYNES A
Citation: N. Thatcher et al., PHASE-III STUDY OF PACLITAXEL (TAXOL(R)) (T) VERSUS BEST SUPPORTIVE CARE (BSC) IN INOPERABLE NONSMALL CELL LUNG-CANCER (NSCLC), Annals of oncology, 9, 1998, pp. 4-4
Authors:
RANSON M
HOWELL A
CARMICHAEL J
OBYRNE K
STEWART S
SMITH D
Citation: M. Ranson et al., STEALTH LIPOSOMAL DIXORUBICIN IN THE TREATMENT OF ADVANCED BREAST-CANCER, Annals of oncology, 9, 1998, pp. 47-47
Authors:
RANSON M
ANDRONICOS NM
OMULLANE MJ
BAKER MS
Citation: M. Ranson et al., INCREASED PLASMINOGEN BINDING IS ASSOCIATED WITH METASTATIC BREAST-CANCER CELLS - DIFFERENTIAL EXPRESSION OF PLASMINOGEN BINDING-PROTEINS, British Journal of Cancer, 77(10), 1998, pp. 1586-1597
Authors:
RANSON M
OBYRNE K
CARMICHAEL J
SMITH D
STEWART S
HOWELL A
Citation: M. Ranson et al., PHASE-II DOSE-FINDING TRIAL OF CAELYX(TM) (STEALTH(R) LIPOSOMAL DOXORUBICIN HCL) IN THE TREATMENT OF ADVANCED BREAST-CANCER, European journal of cancer, 33, 1997, pp. 658-658
Authors:
YOUNG RI
RANSON M
CHANG J
LORD B
TESTA N
SCARFFE JH
Citation: Ri. Young et al., PHASE-II TRIAL OF RHIL-6 (INTERLEUKIN-6) PRIOR TO AND CONCURRENTLY WITH VAD (VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE) CHEMOTHERAPY FOR PATIENTS WITH MULTIPLE-MYELOMA, European journal of cancer, 33(2), 1997, pp. 307-311
Authors:
CLEMONS M
LEAHY M
VALLE J
JAYSON G
RANSON M
HAYES S
HOWELL A
Citation: M. Clemons et al., REVIEW OF RECENT TRIALS OF CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - STUDIES EXCLUDING TAXANES, European journal of cancer, 33(13), 1997, pp. 2171-2182
Authors:
CLEMONS M
LEAHY M
VALLE J
JAYSON G
RANSON M
HOWELL A
Citation: M. Clemons et al., REVIEW OF RECENT TRIALS OF CHEMOTHERAPY FOR ADVANCED BREAST-CANCER - THE TAXANES, European journal of cancer, 33(13), 1997, pp. 2183-2193
Authors:
ANDRONICOS NM
RANSON M
BOGNACKI J
BAKER MS
Citation: Nm. Andronicos et al., THE HUMAN ENO1 GENE-PRODUCT (RECOMBINANT HUMAN ALPHA-ENOLASE) DISPLAYS CHARACTERISTICS REQUIRED FOR A PLASMINOGEN BINDING-PROTEIN, Biochimica et biophysica acta. Protein structure and molecular enzymology, 1337(1), 1997, pp. 27-39
Authors:
THATCHER N
JAYSON G
BRADLEY B
RANSON M
ANDERSON H
Citation: N. Thatcher et al., GEMCITABINE - SYMPTOMATIC BENEFIT IN ADVANCED NONSMALL CELL LUNG-CANCER, Seminars in oncology, 24(3), 1997, pp. 86-812
Authors:
WRIGLEY E
WEAVER A
JAYSON G
RANSON M
RENNINSON J
PRENDIVILLE J
DOBSON M
COLLINS CD
SWINDELL R
BUCKLEY CH
RADFORD JA
CROWTHER D
Citation: E. Wrigley et al., A RANDOMIZED TRIAL INVESTIGATING THE DOSE INTENSITY OF PRIMARY CHEMOTHERAPY IN PATIENTS WITH OVARIAN-CARCINOMA - A COMPARISON OF CHEMOTHERAPY GIVEN EVERY 4 WEEKS WITH THE SAME CHEMOTHERAPY GIVEN AT 3 WEEK INTERVALS, Annals of oncology, 7(7), 1996, pp. 705-711
Authors:
RANSON M
HOWELL A
CHEESEMAN S
MARGISON J
Citation: M. Ranson et al., LIPOSOMAL DRUG-DELIVERY, Cancer treatment reviews, 22(5), 1996, pp. 365-379
Authors:
BETTICHER DC
ANDERSON H
RANSON M
THATCHER N
HABBOUBI N
MEELY K
Citation: Dc. Betticher et al., A PHASE-II EVALUATION OF BONE-MARROW PROTECTION BY ETHYOL(R) (AMIFOSTINE) (AM) IN PATIENTS WITH NON-SMALL-CELL LUNG-CANCER (NSCLC) TREATED WITH CARBOPLATIN (C), European journal of cancer, 31A, 1995, pp. 1058-1058
Authors:
THATCHER N
ANDERSON H
BETTICHER DC
RANSON M
Citation: N. Thatcher et al., SYMPTOMATIC BENEFIT FROM GEMCITABINE AND OTHER CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG-CANCER - CHANGES IN PERFORMANCE STATUS AND TUMOR-RELATED SYMPTOMS, Anti-cancer drugs, 6, 1995, pp. 39-48
Authors:
RANSON M
THATCHER N
Citation: M. Ranson et N. Thatcher, THE IMPORTANCE OF DOSE AND SCHEDULE IN CHEMOTHERAPY FOR SMALL-CELL LUNG-CANCER, Anti-cancer drugs, 6, 1995, pp. 53-63
Authors:
RANSON M
TICKLE C
MAHON KA
MACKEM S
Citation: M. Ranson et al., GNOT1, A MEMBER OF A NEW HOMEOBOX GENE SUBFAMILY, IS EXPRESSED IN A DYNAMIC, REGION-SPECIFIC DOMAIN ALONG THE PROXIMODISTAL AXIS OF THE DEVELOPING LIMB, Mechanisms of development, 51(1), 1995, pp. 17-30
Authors:
THATCHER N
RANSON M
LEE SM
NIVEN R
ANDERSON H
Citation: N. Thatcher et al., CHEMOTHERAPY IN NON-SMALL-CELL LUNG-CANCER, Annals of oncology, 6, 1995, pp. 83-95
Authors:
RANSON M
Citation: M. Ranson, TRANSPORT OF ANIMALS, Veterinary record, 136(20), 1995, pp. 523-523
Authors:
KNEZEVIC V
RANSON M
MACKEM S
Citation: V. Knezevic et al., THE ORGANIZER-ASSOCIATED CHICK HOMEOBOX GENE, GNOT1, IS EXPRESSED BEFORE GASTRULATION AND REGULATED SYNERGISTICALLY BY ACTIVIN AND RETINOICACID, Developmental biology, 171(2), 1995, pp. 458-470
Authors:
BETTICHER DC
ANDERSON H
RANSON M
MEELY K
OSTER W
THATCHER N
Citation: Dc. Betticher et al., CARBOPLATIN COMBINED WITH AMIFOSTINE, A BONE-MARROW PROTECTANT, IN THE TREATMENT OF NON-SMALL-CELL LUNG-CANCER - A RANDOMIZED PHASE-II STUDY, British Journal of Cancer, 72(6), 1995, pp. 1551-1555
Authors:
ANDERSON H
SCARFFE JH
RANSON M
YOUNG R
WIERINGA GS
MORGENSTERN GR
FITZSIMMONS L
RYDER D
Citation: H. Anderson et al., VAD CHEMOTHERAPY AS REMISSION INDUCTION FOR MULTIPLE-MYELOMA, British Journal of Cancer, 71(2), 1995, pp. 326-330
Authors:
CILLARD J
PEREZ S
CILLARD P
SERGENT O
MOREL I
RANSON M
Citation: J. Cillard et al., STUDY OF PROTECTIVE EFFECT OF HIGHLY POLYMERIZED DEOXYRIBONUCLEOTIDES(HPDR) AGAINST LIPID-PEROXIDATION, STP pharma sciences, 4(5), 1994, pp. 359-365
Authors:
MCLEOD SD
RANSON M
MASON RS
Citation: Sd. Mcleod et al., EFFECTS OF ESTROGENS ON HUMAN MELANOCYTES IN-VITRO, Journal of steroid biochemistry and molecular biology, 49(1), 1994, pp. 9-14
Authors:
WOLL PJ
RANSON M
MARGISON J
THOMSON Y
VANDERWATER L
GEORGE N
HOWELL A
Citation: Pj. Woll et al., SURAMIN FOR BREAST AND PROSTATE-CANCER - A PILOT-STUDY OF INTERMITTENT SHORT INFUSIONS WITHOUT ADAPTIVE-CONTROL, Annals of oncology, 5(7), 1994, pp. 597-600
Authors:
VANHOEF MEHM
BAUMANN I
LANGE C
LUFT T
DEWYNTER EA
RANSON M
MORGENSTERN GR
YVERS A
DEXTER TM
TESTA NG
HOWELL A
Citation: Mehm. Vanhoef et al., DOSE-ESCALATING INDUCTION CHEMOTHERAPY SUPPORTED BY LENOGRASTIM PRECEDING HIGH-DOSE CONSOLIDATION CHEMOTHERAPY FOR ADVANCED BREAST-CANCER -SELECTION OF THE MOST ACCEPTABLE REGIMEN TO INDUCE MAXIMAL TUMOR RESPONSE AND INVESTIGATION OF THE OPTIMAL TIME TO COLLECT PERIPHERAL-BLOODPROGENITOR CELLS FOR HEMATOLOGICAL RESCUE AFTER HIGH-DOSE CONSOLIDATION CHEMOTHERAPY, Annals of oncology, 5(3), 1994, pp. 217-224